Skip to main content
padlock icon - secure page this page is secure

Promising Strategies for Obesity Pharmacotherapy: Melanocortin-4 (MC- 4) Receptor Agonists and Melanin Concentrating Hormone (MCH) Receptor-1 Antagonists

Buy Article:

$68.00 + tax (Refund Policy)

Despite remarkable progress in the elucidation of energy balance and regulation, the development of new antiobesity drugs is still at the stage of infancy. Herein we briefly reviewed several investigational anti-obesity agents currently under development, consisting of agents controlling appetite, modulating nutrient absorption and lipid metabolism, sensing and regulating nutrient status, stimulating energy expenditure, and reducing adiposity. In particular, two promising targets such as melanocortin-4 (MC-4) receptor and melanin concentrating hormone (MCH)-1 receptor will be highlighted in this review covering major medicinal chemistry efforts and biological aspects of the compounds synthesized. Considering the enthusiastic efforts to develop efficacious and safe anti-obesity drugs, a range of novel medications treating obesity more effectively than is currently managed by pharmacotherapy will be available in near future.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Anti-obesity drugs; energy homeostasis; melanin concentrating hormone; melanocortin-4; weight loss

Document Type: Research Article

Affiliations: Center for Metabolic Syndrome Therapeutics, Bio-Organic Science Division, Korea Research Institute of Chemical Technology, Jang-dong 100, Yuseong-gu, Daejeon, Korea 305-343.

Publication date: April 1, 2009

More about this publication?
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more